Italian medical device firm Sorin Group has secured CE Mark approval for its new mitral valve annuloplasty ring, Memo 3D ReChord.
Memo 3D ReChord is a repair device developed to deliver better patient outcomes, while facilitating the surgical procedure. It is now commercially available in Europe.
Dr Mattia Glauber presented the first implantation of the ring at the European Association for Cardiothoracic Surgery (EACTS) techno-college session.
The device offers a portfolio of solutions for all types of mitral valve disease, and enables preservation of the native valve, allowing patients to resume a normal lifestyle after surgery.
It features a new chordal guiding system, which makes artificial chordae tendineae replacement a routine and standardised procedure.
Dr Glauber said: "The MEMO 3D ReChord is very easy to place, and the chordal system is indeed very useful, especially in minimally invasive surgery. I have tried it in both anterior and posterior prolapse cases, and it worked nicely in both situations without the need for further adjustments.
"Of course, we need to gain more experience to be able to guide surgeons to the correct indication, but this first experience was extremely positive.
"In my opinion, this device has the potential to change the approach to mitral valve repair. We are facing a situation where we are resecting less and less while using more artificial chords; therefore, a system that helps to standardise artificial chord replacement is very timely."
The system features Carbofilm coating and laser cut Ni-Ti technology, which improves physiologic performance.
Sorin Group cardiac surgery business unit president Michel Darnaud said: "Memo 3D ReChord is the latest result of our continuous effort to bring innovation to cardiac surgery teams. It represents a great opportunity to advance our presence in the mitral valve repair market.
"It has been engineered to fulfil the growing demand for faster and more reproducible artificial chord replacement. We are committed to setting high standards in design and performance to support patients and cardiac surgeons in the management of mitral valve disease."
The company is focused on developing and marketing medical technologies for cardiac surgery, as well as for the treatment of cardiac rhythm disorders.
Image: Memo 3D Rechord annuloplasty ring. Photo: courtesy of Business Wire/Sorin Group.